As mentioned above, we demonstrate the oncogenic role of LIF in HCC by exploiting LIF inhibition as a potential therapeutic strategy and identifying CVB‐D as the first established LIF inhibitor to improve potential HCC therapeutics. Here, LIF is linked to hepatocellular carcinoma.